Investor Alert: Abbott Cooper PLLC Investigates Prelude Therapeutics Incorporated; Urges Prelude Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) — Abbott Cooper PLLC is investigating Prelude Therapeutics Incorporated (NASDAQ: PRLD) (“Prelude” or the “Company”) on behalf of the Company’s investors.
The objective of this investigation is to determine whether Prelude’s board of directors (the “Board”) violated fiduciary duties owed to Prelude stockholders in connection with certain provisions in Prelude’s bylaws that may have the effect of entrenching the Board and insulating Prelude’s directors from being held accountable by Prelude stockholders.
Prelude stockholders are encouraged to contact Abbott Cooper PLLC by calling (475) 333-0674, emailing [email protected] or visiting our website at www.abbottlawyer.com for additional information about this investigation as well as their legal rights and options.
Abbott Cooper PLLC is dedicated to shareholders’ rights and empowering shareholders through strategic counsel and legal advocacy. For additional information about Abbott Cooper PLLC, please visit www.abbottlawyer.com.
CONTACT:
Abbott Cooper PLLC
Abbott Cooper
(475) 333-0674
www.abbottlawyer.com
Attorney advertising. Prior results do not guarantee a similar outcome.
